[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628629":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":20,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":20,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":65,"conditions":66,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NI-FAPI group","EXPERIMENTAL","Injection of \\[68Ga\\]Ga-NI-FAPI",[13],"Drug: Injection of 68Ga-NI-FAPI",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Injection of 68Ga-NI-FAPI","Subjects were injected with 68Ga-NI-FAPI at 0.4-0.5mci\u002Fkg body weight",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Zhu","CONTACT","+86-13021115973","yfwyw1999@126.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":20,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":25,"phoneExt":20,"email":26},"Wang",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Zhaohui Zhu","Chief physician","100628629","phase-1-application-of-68gaga-ni-fapi-04-petct-imaging-in-fibroblast-activation-protein-related-diseases-100628629",false,"NCT07464132","Application of [68Ga]Ga-NI-FAPI-04 PET\u002FCT Imaging in Fibroblast Activation Protein Related Diseases","Inclusion Criteria:\n\n* 1: 18-85 years old\n\n  2: Tumor patients can undergo surgery or biopsy to obtain pathological diagnosis\n\n  3: Ability to understand and sign informed consent forms\n\n  4: Expected survival period exceeding 6 months and able to receive follow-up\n\n  5: Healthy volunteers without chronic medical history of hypertension, diabetes, coronary heart disease, kidney disease, tumor, etc\n\nExclusion Criteria:\n\n* 1: Pregnant or lactating women\n\n  2: Patients allergic to research drug ingredients\n\n  3: Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μ mol\u002FL)\n\n  4: Patients who participate in other clinical trials and interfere with the results of this study\n\n  5: Patients with severe illness who cannot cooperate with the examination",true,"ALL","18 Years","85 Years",{"count":59,"type":60},30,"ESTIMATED","INTERVENTIONAL",[63,64],"PHASE1","PHASE2","The purpose of this study is to conduct clinical research on \\[68Ga\\] Ga-NI-FAPI-04 PET\u002FCT imaging and further investigate its diagnostic value in fibroblast activation related diseases.",[67,68,69,70,71,72],"Tumor","Cardiovascular Diseases","Pulmonary Fibrosis","Rheumatic Immune Diseases Involving Large Blood Vessels","Hypertrophic Cardiomyopathy (HCM)","Other Hypoxic and Fibroblast Activated Diseases","2026-03-09",{"date":75,"type":76},"2026-03-11","ACTUAL",{"date":78,"type":76},"2025-12-17",{"date":80,"type":60},"2027-06-17",{"name":5,"class":6},1]